FGF2 and prostate carcinoma: Accordingly, ARPCA suppresses the angiogenic and tumorigenic potential of prototypic androgen/FGF8b-dependent Shionogi 115 (S115) mammary carcinoma cells [21] and of androgen/FGF8b/FGF2-dependent TRAMP-C2 prostate cancer cells [22].